Zhejiang Huahai Pharmaceutical Future Growth
Future criteria checks 2/6
Zhejiang Huahai Pharmaceutical is forecast to grow earnings and revenue by 21.2% and 12.6% per annum respectively. EPS is expected to grow by 21.4% per annum. Return on equity is forecast to be 14.9% in 3 years.
Key information
21.2%
Earnings growth rate
21.4%
EPS growth rate
| Pharmaceuticals earnings growth | 18.0% |
| Revenue growth rate | 12.6% |
| Future return on equity | 14.9% |
| Analyst coverage | Low |
| Last updated | 22 May 2024 |
Recent future growth updates
Recent updates
Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 20
Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt
May 28There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings
May 06Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel
Mar 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 12,176 | 1,679 | N/A | N/A | 1 |
| 12/31/2025 | 11,492 | 1,464 | N/A | 1,616 | 2 |
| 12/31/2024 | 9,896 | 1,184 | N/A | 1,582 | 2 |
| 3/31/2024 | 8,748 | 928 | 1,139 | 2,696 | N/A |
| 12/31/2023 | 8,309 | 830 | 625 | 2,217 | N/A |
| 9/30/2023 | 8,635 | 1,095 | 116 | 2,096 | N/A |
| 6/30/2023 | 8,736 | 1,169 | -531 | 1,643 | N/A |
| 3/31/2023 | 8,552 | 1,203 | -772 | 1,515 | N/A |
| 12/31/2022 | 8,266 | 1,168 | -1,074 | 1,243 | N/A |
| 9/30/2022 | 7,884 | 692 | -1,482 | 857 | N/A |
| 6/30/2022 | 7,432 | 540 | -1,648 | 1,015 | N/A |
| 3/31/2022 | 6,919 | 370 | -1,514 | 975 | N/A |
| 12/31/2021 | 6,644 | 488 | -1,496 | 938 | N/A |
| 9/30/2021 | 6,212 | 679 | -994 | 1,068 | N/A |
| 6/30/2021 | 6,215 | 867 | -285 | 1,341 | N/A |
| 3/31/2021 | 6,412 | 964 | -282 | 1,265 | N/A |
| 12/31/2020 | 6,485 | 930 | 279 | 1,555 | N/A |
| 9/30/2020 | 6,247 | 898 | 546 | 1,670 | N/A |
| 6/30/2020 | 6,041 | 813 | 858 | 1,774 | N/A |
| 3/31/2020 | 5,760 | 655 | 1,054 | 1,877 | N/A |
| 12/31/2019 | 5,388 | 570 | 960 | 1,754 | N/A |
| 9/30/2019 | 5,263 | 364 | 391 | 1,340 | N/A |
| 6/30/2019 | 5,209 | 213 | -280 | 740 | N/A |
| 3/31/2019 | 5,055 | 81 | -538 | 560 | N/A |
| 12/31/2018 | 5,095 | 108 | -1,057 | 68 | N/A |
| 9/30/2018 | 5,335 | 409 | -630 | 506 | N/A |
| 6/30/2018 | 5,190 | 573 | -396 | 644 | N/A |
| 3/31/2018 | 5,112 | 661 | -360 | 518 | N/A |
| 12/31/2017 | 5,002 | 639 | N/A | 646 | N/A |
| 9/30/2017 | 4,680 | 601 | N/A | 222 | N/A |
| 6/30/2017 | 4,460 | 537 | N/A | 231 | N/A |
| 3/31/2017 | 4,254 | 519 | N/A | 306 | N/A |
| 12/31/2016 | 4,093 | 501 | N/A | 433 | N/A |
| 9/30/2016 | 4,001 | 492 | N/A | 453 | N/A |
| 6/30/2016 | 3,848 | 466 | N/A | 325 | N/A |
| 3/31/2016 | 3,738 | 464 | N/A | 238 | N/A |
| 12/31/2015 | 3,500 | 442 | N/A | 195 | N/A |
| 9/30/2015 | 3,201 | 399 | N/A | 262 | N/A |
| 6/30/2015 | 3,071 | 372 | N/A | 262 | N/A |
| 3/31/2015 | 2,793 | 313 | N/A | 258 | N/A |
| 12/31/2014 | 2,585 | 266 | N/A | 329 | N/A |
| 9/30/2014 | 2,406 | 277 | N/A | 217 | N/A |
| 6/30/2014 | 2,220 | 265 | N/A | 419 | N/A |
| 3/31/2014 | 2,224 | 310 | N/A | 433 | N/A |
| 12/31/2013 | 2,296 | 359 | N/A | 490 | N/A |
| 9/30/2013 | 2,295 | 404 | N/A | 496 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600521's forecast earnings growth (21.2% per year) is above the savings rate (2.9%).
Earnings vs Market: 600521's earnings (21.2% per year) are forecast to grow slower than the CN market (22.2% per year).
High Growth Earnings: 600521's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 600521's revenue (12.6% per year) is forecast to grow slower than the CN market (13.7% per year).
High Growth Revenue: 600521's revenue (12.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600521's Return on Equity is forecast to be low in 3 years time (14.9%).